



Management of (UA or NSTEMI)

- The recommended dose of Fondaparinux Sodium Injection is 2.5 mg once daily, administered by subcutaneous injection.
- Treatment should be initiated as soon as possible following diagnosis and may be continued for up to 8 days or until hospital discharge.
- If a patient is to undergo percutaneous coronary intervention (PCI) while being treated with Fondaparinux Sodium Injection, an effective anti-thrombin regimen such as unfractionated heparin (UFH) should be administered as an adjunct to PCI, as per standard practice
- The timing of the next dose of subcutaneous Fondaparinux Sodium Injection after sheath removal should be based on clinical judgment. In the UA/NSTEMI clinical trials treatment with Fondaparinux Sodium Injection was restarted no earlier than 2 hours after sheath removal.
- In patients who are to undergo Coronary Artery Bypass Graft (CABG) surgery, Fondaparinux Sodium Injection where possible, should not be given during the 24 hours before surgery and may be restarted 48 hours post-operatively.